{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Number of participants who experience severe chronic GVHD requiring additional immunosuppressive therapy by Day 360. All participants are evaluable.","groups":[{"description":"Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.\n\nFludarabine: Days -6 through -2: 30 mg/m\\^2 IV daily\n\nCyclophosphamide: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily\n\nTotal body irradiation: Day -1: 200 cGy in a single fraction\n\nTacrolimus: Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.\n\nMycophenolate mofetil: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)","id":"OG000","title":"PBSCT D90"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Of the 57 patients in the D90 cohort, 33 stopped tacrolimus early as planned.","reportingStatus":"POSTED","timeFrame":"Day 360","title":"Number of Number of Participants With Severe Chronic GVHD, Day 360 (D90)","type":"SECONDARY","unitOfMeasure":"Participants"}